Welcome to our dedicated page for Emergent Biosolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how BARDA contracts affect Emergent BioSolutions’ cash flow can feel like hunting for anthrax spores in a 300-page 10-K. Footnotes on NARCAN sales, vaccine stockpile renewals, and facility inspections are scattered across multiple exhibits, making even seasoned analysts scroll endlessly. This page is where you’ll find Emergent BioSolutions SEC filings explained simply, without missing a single nuance.
Stock Titan solves that problem with AI-powered summaries that translate every filing into plain English. When an Emergent BioSolutions quarterly earnings report 10-Q filing hits EDGAR, our engine highlights year-over-year commercial-segment trends in minutes. Need to spot an Emergent BioSolutions 8-K material events explained? You’ll receive a real-time alert the moment it’s posted.
- Instant view of Emergent BioSolutions insider trading Form 4 transactions
- Emergent BioSolutions Form 4 insider transactions real-time push notifications for executive stock moves
- Emergent BioSolutions annual report 10-K simplified with section-by-section AI notes
- Clear Emergent BioSolutions proxy statement executive compensation breakdowns
- Actionable Emergent BioSolutions earnings report filing analysis each quarter
These tools help you compare manufacturing capacity disclosures across sites, verify government contract backlogs, and monitor Emergent BioSolutions executive stock transactions Form 4 before making portfolio decisions. Whether you’re understanding Emergent BioSolutions SEC documents with AI or exporting tables for a model, Stock Titan keeps every detail one click away—no more wading through dense biotech jargon.
Emergent Biosolutions (EBS) reported a Form 144 notice to sell restricted common stock. The filing shows an intended sale of 7,086 shares with an aggregate market value of $62,852.82, representing part of a total 53,351,099 shares outstanding. The proposed approximate sale date is 08/15/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The shares to be sold were acquired as restricted stock: 6,101 shares on 05/08/2025 and 985 shares on 05/25/2025, with payment recorded on the acquisition dates. The filer reports no securities sold by the same person during the past three months and makes the required representation about material nonpublic information.
Donald W. DeGolyer, a director of Emergent BioSolutions (EBS), sold 7,844 shares of common stock on 08/12/2025 at an exact price of $8.6475 per share to satisfy tax obligations arising from the settlement of vested restricted stock units (RSUs) on 05/22/2025. After this tax-withholding sale the reporting person directly beneficially owns 137,659 shares. The filing lists the transaction code "S" and provides the explanation that the sale was executed solely to satisfy tax withholding related to the RSU settlement.
Emergent Biosolutions (EBS) filed a Form 144 reporting a proposed sale of 7,844 shares of common stock that were acquired as restricted stock from the issuer on 05/08/2025. The filing lists an aggregate market value of $67,830.99 for the shares and shows 53,351,099 shares outstanding for the issuer. The seller reports an approximate date of sale of 08/12/2025 and the transaction is to occur on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The form indicates no securities sold in the past three months by the person for whose account these securities are to be sold and includes the standard representation that the signer does not possess undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
